To analyze the situation and clinical characteristics of adverse drug reactions induced by brentuximab vedotin, so as to provide reference for clinical safe and rational drug use.

By searching the literature in CNKI, Wanfang, database, VIP, CBM, Embase, and PubMed, the adverse drug reaction cases after the marketing of brentuximab vedotin were collected and statistically analyzed.

A total of 24 literatures were involved and 254 patients were included. Adverse drug reactions induced by brentuximab vedotin mainly involved nervous system damage (30.13%), blood system damage (26.50%), immune dysfunction (9.62%), skin and subcutaneous tissue disorders (8.97%), systemic reaction (8.33%), with the specific performance of peripheral neuropathy, neutropenia, infections, infusion reaction, elevated transaminase levels, thrombocytopenia, rashes, and so on. Most of the patients with adverse reactions had good prognosis. Nine cases of death were reported, including interstitial lung disease (n=3), pneumonia (n=2), progressive multifocal leukoencephalopathy (n=2), heart failure (n=1) and acute liver injury (n=1).

The doctors and pharmacists should pay attention to the adverse drug reactions by brentuximab vedotin. The adverse drug reaction monitoring should be strengthened, with the adverse drug reactions detected and dealt in time, so as to ensure the medication safety of patients.